In short
This article discusses an ongoing clinical trial investigating the use of BNT113, a novel drug, in combination with pembrolizumab for treating patients with advanced head and neck squamous cell carcinoma (HNSCC) that is positive for human papillomavirus 16 (HPV16+) and expresses PD-L1. The study aims to compare this combination therapy with pembrolizumab alone in terms of safety, tolerability, and effectiveness in improving overall survival and tumor response rates.
At a glance
- Trial Type
- Phase II, open-label, randomized
- Study Drug
- BNT113 (containing RBL015.2 and RBL016.2) in combination with pembrolizumab
- Condition
- Unresectable recurrent or metastatic HPV16+ Head and Neck Squamous Cell Carcinoma (HNSCC) expressing PD-L1
- Primary Objectives
- Assess safety and tolerability (Part A), evaluate overall survival and objective response rate (Part B)
- Key Eligibility Criteria
- Adults with confirmed HPV16+ HNSCC, PD-L1 expression, no prior systemic therapy for advanced disease
- Main Exclusion Criteria
- Pregnancy, active infections, certain autoimmune diseases, prior immunotherapy
- Primary Endpoints
- Overall survival, objective response rate
- Secondary Endpoints
- Progression-free survival, duration of response, safety assessments
What is BNT113?
BNT113 is an investigational drug being developed for the treatment of a specific type of head and neck cancer. It is a combination of two active substances called RBL015.2 and RBL016.2. These substances are classified as nucleic acids, which are molecules that carry genetic information in our cells.
Target Condition: HPV16-Positive Head and Neck Cancer
BNT113 is specifically designed to treat head and neck squamous cell carcinoma (HNSCC) that is positive for human papillomavirus 16 (HPV16) and expresses a protein called PD-L1. This type of cancer can affect various parts of the head and neck, including the:
- Oropharynx (part of the throat behind the mouth)
- Oral cavity (mouth)
- Hypopharynx (lower part of the throat)
- Larynx (voice box)
The cancer targeted by BNT113 is considered unresectable (cannot be completely removed by surgery), recurrent (has come back after initial treatment), or metastatic (has spread to other parts of the body).
How BNT113 Works
BNT113 is being studied in combination with another drug called pembrolizumab. While the exact mechanism of action is not fully described in the provided information, it's likely that BNT113 works by stimulating the immune system to recognize and attack cancer cells. Pembrolizumab is known to be an immunotherapy drug that helps the immune system fight cancer.
Clinical Trial Details
A clinical trial is currently underway to evaluate the effectiveness and safety of BNT113 in combination with pembrolizumab. This trial has two main parts:
- Safety run-in phase (Part A): This phase aims to assess the safety and tolerability of BNT113 when used with pembrolizumab.
- Randomized phase (Part B): This phase compares BNT113 plus pembrolizumab to pembrolizumab alone. The main goals are to see if the combination improves overall survival and increases the number of patients whose tumors shrink or disappear (called objective response rate).
Eligibility Criteria
To participate in this clinical trial, patients must meet certain criteria. Some key eligibility factors include:
- Age 18 or older
- Confirmed diagnosis of HPV16-positive head and neck squamous cell carcinoma
- Cancer that expresses the PD-L1 protein
- No prior systemic anticancer therapy for recurrent or metastatic disease
- Measurable disease according to specific criteria
- Adequate organ function (bone marrow, liver, kidney)
There are also several exclusion criteria, such as certain medical conditions or prior treatments that would make a patient ineligible for the study.
Potential Benefits
While the effectiveness of BNT113 is still being studied, the researchers hope to see the following benefits:
- Improved overall survival (patients living longer)
- Higher objective response rate (more tumors shrinking or disappearing)
- Longer progression-free survival (more time before the cancer grows or spreads)
- Longer duration of response (tumors staying smaller for a longer time)
Safety Considerations
As with any investigational treatment, there are potential risks and side effects associated with BNT113. The clinical trial is carefully monitoring for:
- Treatment-emergent adverse events (side effects that occur during treatment)
- Serious or severe side effects
- Side effects that may require dose reduction, delay, or discontinuation of treatment
Patients considering participation in this clinical trial should discuss the potential risks and benefits with their healthcare provider.